SURF — Surface Oncology Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $65.08m
- $8.82m
- $30.00m
Brief: Surface Oncology Announces FDA Fast Track Designation Granted By U.S. Food And Drug Administration For SRF388 To Treat Liver Cancer
Brief: Surface Oncology Announces Q3 Loss Per Share $0.39
Brief: Surface Oncology Reports Financial Results And Corporate Highlights For Third Quarter 2020
Brief: Surface Oncology To Present SRF388 And SRF114 Preclinical Data At Upcoming Society For Immunotherapy For Cancer 2020 Conference
NASDAQ RESUMED AT 03:19 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:02 PM
Surface Oncology: Soars after report says company exploring potential sale
Media: Surface Oncology explores potential sale after GSK takeover approach - Street Insider
U.S. RESEARCH ROUNDUP- Builders Firstsource, General Mills, Surface Oncology
Brief: Surface Oncology Reports Q2 Loss Per Share $0.44
Brief: EcoR1 Capital Reports Passive Stake Of 12.8% In Surface Oncology
Brief: Surface Oncology Files For Common Stock Offering Of Up To $50 Million
U.S. STOCKS ON THE MOVE-Luckin Coffee, Kornit Digital, Xcel Brands
U.S. STOCKS ON THE MOVE-Atossa, Kornit Digital, Xcel Brands
U.S. STOCKS ON THE MOVE-Pyxus, Xcel Brands, Luckin Coffee
Brief: Surface Oncology And Merck To Collaborate On Immuno-Oncology Study Evaluating Srf617, Targeting CD39 In Combination With Keytruda In Solid Tumor Patients
Surface Oncology: Surges on partnering with Merck for cancer therapy
Brief: Surface Oncology Reports Financial Results For Q1 2020
Brief: Surface Oncology- As Of March 31, 2020, Cash, Cash Equivalents And Marketable Securities Were $90.1 Mln